Experimental brain tumor treatment shows promise in early trial
NCT ID NCT02774421
First seen Mar 25, 2026 · Last updated May 06, 2026 · Updated 10 times
Summary
This early-phase study looks at whether giving trastuzumab directly into the spinal fluid, along with an immune-boosting drug called GM-CSF, can help children whose ependymoma brain tumor has come back. The main goals are to see if the drug reaches the tumor and to find the safest dose. About 33 children aged 1 to 21 with a specific type of relapsed ependymoma are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTERIOR FOSSA EPENDYMOMA (PFEPN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.